Marksans Pharma Limited (BOM:524404)
India · Delayed Price · Currency is INR 168.15
+0.15 (0.09%)
At close: Apr 2, 2026
Marksans Pharma Market Cap
Marksans Pharma has a market cap or net worth of 76.2 billion as of April 2, 2026. Its market cap has decreased by -16.42% in one year.
Market Cap
76.20B
Enterprise Value
73.10B
Revenue
28.03B
Ranking
n/a
PE Ratio
21.15
Stock Price
168.15
Market Cap Chart
Since December 13, 2006, Marksans Pharma's market cap has increased from 3.65B to 76.20B, an increase of 1,986.76%. That is a compound annual growth rate of 17.03%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 2, 2026 | 76.20B | -6.73% |
| Dec 31, 2025 | 81.70B | -39.22% |
| Dec 31, 2024 | 134.43B | 84.14% |
| Dec 29, 2023 | 73.00B | 210.96% |
| Dec 30, 2022 | 23.48B | -4.66% |
| Dec 31, 2021 | 24.63B | -0.80% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| AstraZeneca Pharma India | 195.44B |
| Granules India | 152.15B |
| Jubilant Pharmova | 133.01B |
| Rubicon Research | 127.66B |
| Caplin Point Laboratories | 119.17B |
| CORONA Remedies | 91.69B |
| Viyash Scientific | 83.73B |
| Procter & Gamble Health | 79.19B |